MLTX
$16.77
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of in...
Recent News
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update
MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. MoonLake Immunotherapeutics (NASDAQ:MLTX) is placed eighth on our list of most promising stocks. TheFly reported on February 26 that Goldman Sachs increased its price target on MLTX to $11 from $10 and maintained a Sell rating. The update followed […]
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B Ratio
Recent performance snapshot MoonLake Immunotherapeutics (MLTX) has drawn investor interest after a mixed stretch in the stock, with a 1 day decline of 0.96% and a 6.71% drop over the past week, alongside recent gains. Over the past month the share price shows a 7.75% return, and across the past 3 months it is up 27.53%, while the 1 year total return sits at a loss of 58.07%. See our latest analysis for MoonLake Immunotherapeutics. With the share price now at $17.51, MoonLake...
MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data Update - What's Changed
MoonLake Immunotherapeutics recently reported full-year 2025 results showing a wider net loss of US$227.32 million and a basic loss per share of US$3.53, alongside announcing positive topline Phase 2 data for its lead drug candidate sonelokimab in axial spondyloarthritis with no new safety signals. The company also highlighted that more than 80% of patients in the axial spondyloarthritis trial achieved key response endpoints by week 12, while stating it has sufficient cash to fund operations...
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position
Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.